We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Well we will have to agree to disagree on this one.
As for "salting it", I am only stating how I see it.
One thing that is for sure is all the profit will go directly to Provexis from By-Health sales, not split with DSM and there share would have been more than 10%
No one mentioned or suggested generics Gixer, we all know we're talking about FF and that we have patent protection.
Not sure why you and Alfista can't respond to what people are saying without salting it.
This is what I'm seeing from Provexis scope:
manufacturer (3rd party) >>supplier(Provexis)>>Customer(ByHealth)
Seems to put us in the middle.
You might well say that ByHealth then sell on again in various formats, but it's outside our scope in the terms of the supply chain.
I thin that would be bad practice, as it would hand too much control to BH, making it difficult for to separate at the end of the agreement/contract term. Much better if PXS maintain production control and use a third party to produce it. Also they will benefit from economies of scale. Stephen Moon once said that with increased production, the margin goes from good to very high.
Longer term I expect By Health shall set up their own in country FF production
- makes sense as China is the biggest tomato producer
https://edis.ifas.ufl.edu/publication/FE1027
W$
Fruitflow is currently produced by outsourced third party manufacturers in Europe, and it is intended that the Company will have direct access to these manufacturers for its sales of Fruitflow to third parties. The Company and the third party manufacturers are actively engaged in some ongoing production capacity planning, looking at the steps required to scale-up the production of Fruitflow to meet the anticipated increase in demand.
You make it sound like Provexis is buying and selling some generic product like vitamin c. It's not.
Indena is a contract manufacturer and would be manufacturing Fruitflow under contract for Provexis. As though pxs was manufacturing it themselves.
So, to change my first thought. If there is a middleman then that would be By-health as they are buying from the owner and selling on.
Alf, I never suggested we would manufacture ourselves, again, I have no idea where that comes from when I'd say we could buy it from a third party....
If we are responsible for supplying something that someone else manufactures to byhealth, seems to out us in the middle of that chain to me, but there you go, everyone has their own take on it...
Just my opinion but if there is a middle man then surely that would be the manufacturer. Its certainly not provexis.
Well, your previous post, calling Provexis the "middle men".
Even if Provexis expand demand vastly, it will always be more cost effective to use a specialist to make it, but that doesnt make it a "middle man" operation IMHO
Who's suggesting that Alf? Not sure where it's coming from.
That doesn't seem logical to me. Are you suggesting that Provexis should move from their business model of mainly being responsible for developing and maintaining IP and patents, to a specialist manufacturer of the product? How much would that cost, how would a factory be run when production is only required a few times per year?
Was only suggesting we would use a third party for the manufacture...ok so it might not be DSM, still sounds like man in the middle to me...
Just for info in case anyone is not aware.
DSM does not manufacture Fruitflow but instead has a company in Italy/France to do this work and they are called Indena SAS.
Not saying this is were Provexis will have it manufactured but they are already set up and we will not have to go through DSM to buy it.
Barbershop,
Without wanting to sound cheeky. Can I suggest you read the RNS again?
"Provexis will be responsible for the manufacture, supply and sale of its Fruitflow heart-health functional food ingredient to By-Health, and it will contribute scientific expertise necessary for successful commercialisation."
The Agreement between Provexis and By-Health is totally independent to the DSM alliance agreement and 100% of the profit on Fruitflow sold to By-Health will go directly to Provexis and nil to DSM.
https://otp.investis.com/clients/uk/provexis_plc/rns/regulatory-story.aspx?cid=1569&newsid=1523432
Almost sounds like we've set ourselves up to be man in the middle. DSM manufacture, we deliver to By health with a 10% markup.
Thanks Gixer you are a great help
everhopeful, its not an MOU but a long term strategic co-operation framework agreement and it lasts for 10 years, subject to extension and termination clauses.
They don't have the monopoly but do have the exclusive rights to act as the distributor of Fruitflow and sell Fruitflow based functional food and dietary supplement finished products in Mainland China, Hong Kong, Macau, Taiwan and Australia.
Provexis will be responsible for the manufacture, supply and sale of its Fruitflow heart-health functional food ingredient to By-Health.
What comes out of the negotiations with DSM is anyone's guess atm.
Re FF outgrowing PXS and -
We don’t want to be bought out, we want a hugely successful product and excellent profits.
It is the BODs job to get best value for shareholders but we are stuck with a MOU with Byhealth. This might not be a bad thing but there will be no competition as Byhealth has the monopoly . I haven't spent time I should have done looking into it all , I imagine and hope that DSM have a foot hold in the on going future production in China , if that is the case then there isn't as much wriggle room.
There seems to be a total disconnect between the academic field, where the link between sticky blood and Fruitflow as a therapy is discussed more and more, and the commercial field where we don't see any acceleration announcements . If this association is being brought to the attention of medics, it may spark the interest of many more companies than the usual suspects we know about IMHO. Given the "trading torpor" we have witnessed of late, surely something has to break ?
gixer
thanks for the info :-), looks like we are getting noticed !!
I can't help getting the feeling FF is outgrowing PXS....
WS
Came across that one this morning as well :)
Looks like it made reference to our own Med Hypotheses
"Platelet hyperactivity in COVID-19: can the tomato extract Fruitflow® be used as an antiplatelet regime?"
Hope this link works https://bit.ly/32Z3mxv
Google Scholar alert for Fruitflow flagged this paper today, published last week . All about platelets but unable to get free read of paper to see whether FF actually mentioned
https://www.tandfonline.com/doi/full/10.1080/09537104.2021.1961718
Coagulopathy is an evident complication of COVID-19 with predominance of a prothrombotic state. Platelet activation plays a key role. The terms “hyper-reactivity” and “hyperactivity” used in recent literature may not be clear or sufficient to explain the pathological events involved in COVID-related thrombosis (CRT). Inflammation may play a bigger role compared to thrombosis in COVID-related mortality because a smaller percentage of patients with COVID-19 die due to direct effects of thrombosis. Not all COVID-19 patients have thrombocytopenia and a few show thrombocytosis. We believe the platelet pathology is more complex than just activation or hyper-activation, particularly due to the platelets’ role in inflammation. Understanding the pathology and consequences of platelets’ role may help optimize management strategies and diminish CRT-associated morbidity and mortality. In this viewpoint report, we examine the published evidence of platelet hyper-reactivity in COVID-19 with a focused analysis of the key pathologies, diverse alterations, disease outcomes, and therapeutic targets. We believe that COVID-19 is a disease of inflammation and pathologic platelets, and based on the complexity and diverse pathologies, we propose the term “thrombocytopathy” as a more reflective term of the platelets’ involvement in COVID-19. In our opinion, thrombocytopathy is the unpredictable pathologic alterations of platelets in function, morphology and number, caused by different factors with a variety of presentations.
WS
I agree with you, but think that it won't be our choice. The big holders, and board, will have the choice.
We don’t want to be bought out, we want a hugely successful product and excellent profits.